
OXFD
Healthcare · Diagnostics & Research · $562.5M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2020
EPS trend, 90 days to now · 0.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 3, 2020 | After the close | -0.05 | -0.01 | +78.2% |
| Aug 4, 2020 | After the close | -0.30 | -0.37 | -21.4% |
| May 5, 2020 | After the close | -0.15 | -0.23 | -49.1% |
| Mar 2, 2020 | After the close | -0.09 | -0.06 | +35.9% |
| Nov 5, 2019 | After the close | -0.03 | 0.03 | +219.5% |
| Aug 6, 2019 | After the close | -0.05 | 0.02 | +140.6% |
| May 9, 2019 | After the close | -0.20 | -0.06 | +69.8% |
| Mar 11, 2019 | After the close | -0.15 | 5.23 | +3547.6% |
| Nov 9, 2018 | After the close | -0.10 | -0.13 | -25.0% |
| Jul 31, 2018 | After the close | -0.25 | -0.25 | +0.5% |
| May 1, 2018 | After the close | -0.45 | -0.40 | +11.8% |
| Feb 27, 2018 | After the close | -0.36 | 0.33 | +192.1% |
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States, Europe, Asia, and internationally. The company develops its products using its T-SPOT technology platform that measures marker-specific cellular (T cells) responses at a single cell level and inform the diagnosis, prognosis, and monitoring of…